VIVIMUSTA.COM: Keyword Density Checker

Total words: 5906 | 2-word phrases: 1564 | 3-word phrases: 1759 | 4-word phrases: 1824

PAGE INFO

Title	Try to keep the title under 60 characters (40 characters) Vivimusta® (bendamustine HCl Injection)
Description	Try to keep the meta description between 50 - 160 characters (206 characters) Vivimusta® is indicated for adults with Chronic Lymphocytic Leukemia (CLL) and indolent B-cell Non-Hodgkin Lymphoma (NHL) that has advanced within six months of rituximab or a rituximab-containing regimen.
Keywords	Meta keywords are not recommended anymore (0 characters)
H1	H1 tag on the page (41 characters) When choosing a bendamustine formulation,

#	Keyword	Frequency	Density
1	treatment with vivimusta	10	0.57%
2	during treatment with	9	0.51%
3	with bendamustine hcl	9	0.51%
4	azurity pharmaceuticals inc	8	0.45%
5	in patients with	6	0.34%
6	with vivimusta and	6	0.34%
7	vivimusta and for	6	0.34%
8	the last dose	6	0.34%
9	in patients who	6	0.34%
10	clinical trials and	5	0.28%
11	in clinical trials	5	0.28%
12	have been reported	5	0.28%
13	been established in	4	0.23%
14	vivimusta in patients	4	0.23%
15	3 times uln	4	0.23%
16	alternative therapies that	4	0.23%
17	therapies that are	4	0.23%
18	that are not	4	0.23%
19	administration of vivimusta	4	0.23%
20	with rituximab or	4	0.23%
21	of the potential	4	0.23%
22	after the last	4	0.23%
23	use vivimusta in	4	0.23%
24	contraception during treatment	4	0.23%
25	impairment do not	4	0.23%
26	patients who have	4	0.23%
27	reproductive potential to	4	0.23%
28	potential to use	4	0.23%
29	vivimusta consider alternative	4	0.23%
30	to use effective	4	0.23%

#	Keyword	Frequency	Density
1	during treatment with vivimusta	9	0.49%
2	with vivimusta and for	6	0.33%
3	vivimusta in patients with	4	0.22%
4	and may result in	4	0.22%
5	after the last dose	4	0.22%
6	not been established in	4	0.22%
7	therapies that are not	4	0.22%
8	alternative therapies that are	4	0.22%
9	consider alternative therapies that	4	0.22%
10	vivimusta consider alternative therapies	4	0.22%
11	in clinical trials and	4	0.22%
12	administered to a pregnant	4	0.22%
13	to a pregnant woman	4	0.22%
14	in patients who have	4	0.22%
15	concentrations and may result	4	0.22%
16	reproductive potential to use	4	0.22%
17	potential to use effective	4	0.22%
18	use vivimusta in patients	4	0.22%
19	adverse reactions ≥15 for	4	0.22%
20	females and males of	4	0.22%
21	sodium chloride injection usp	3	0.16%
22	and in postmarketing reports	3	0.16%
23	trials and in postmarketing	3	0.16%
24	clinical trials and in	3	0.16%
25	bcell nonhodgkin lymphoma nhl	3	0.16%
26	have been reported with	3	0.16%
27	reported with bendamustine hcl	3	0.16%
28	has not been established	3	0.16%
29	patients in clinical trials	3	0.16%
30	anaphylactic and anaphylactoid reactions	3	0.16%
31	llc a subsidiary of	3	0.16%
32	of azurity pharmaceuticals inc	3	0.16%
33	azurity pharmaceuticals inc ©	3	0.16%
34	a subsidiary of azurity	3	0.16%
35	subsidiary of azurity pharmaceuticals	3	0.16%
36	slayback pharma llc a	3	0.16%
37	pharma llc a subsidiary	3	0.16%
38	please see accompanying full	2	0.11%
39	and during treatment with	2	0.11%
40	in some patients most	2	0.11%

#	URL	Whois	Check
1	http://www.fda.gov/MedWatch	Whois	fda.gov
2	https://www.VivimustaCONNECT.com	Whois	VivimustaCONNECT.com
3	https://www.VivimustaCONNECT.com	Whois	VivimustaCONNECT.com
4	http://www.fda.gov/MedWatch	Whois	fda.gov
5	https://azurity.com/contact-us/	Whois	azurity.com
6	https://azurity.com/contact-us/	Whois	azurity.com